Goriacko Pavel, Golestaneh Ladan, Di Palo Katherine E
Center for Health Data Innovations, Montefiore Einstein, Bronx, NY, USA.
Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
Open Access Emerg Med. 2024 Dec 5;16:305-312. doi: 10.2147/OAEM.S478693. eCollection 2024.
To investigate the clinical utility of administering patiromer as an adjunct to insulin for potassium reduction in patients presenting to the emergency department (ED) with hyperkalemia.
This retrospective cohort study used electronic health record data to identify adults treated with at least one intravenous dose of regular insulin for hyperkalemia within the ED. Patients who were administered patiromer within one hour before or after their insulin dose were categorized as the intervention group. Matching was performed at a 1:1 ratio. The primary outcome, mean change in potassium from baseline to the latest value within the 4-12 hour interval, was compared. Secondary outcomes included net clinical benefit, defined as the mean difference in the number of potassium-lowering interventions minus the change in potassium.
The final analysis included 133 patients treated with patiromer plus insulin and 133 patients treated with insulin alone. Participants had a mean age of 71 years; 43% were female, 31% self-identified as Black, and 38% self-identified as Latinx. No significant changes were observed in potassium from baseline (mean levels 6.2 mEq/L in each group) to the 4-12 hour time frame (patiromer: -0.90 mEq/L, n=78 vs insulin-only: -0.98 mEq/L, n=81; p = 0.51). The calculated net clinical benefit of potassium reduction was -0.25 in favor of the patiromer plus insulin group; however, this difference did not reach statistical significance. In the subgroup of eGFR >30 mL/min, patiromer group received numerically less potassium-lowering interventions (0.63 vs 1.12, p = 0.057).
In this study of patients with acute hyperkalemia in the ED setting, concurrent administration of patiromer did not result in more sustained potassium reduction compared to insulin alone in the overall cohort. The trend in favor of adjunct patiromer in the subgroup with adequate renal function warrants further investigation.
探讨在急诊科(ED)因高钾血症就诊的患者中,给予帕替罗姆作为胰岛素辅助药物降低血钾的临床效用。
这项回顾性队列研究使用电子健康记录数据,以识别在ED内接受至少一剂静脉注射正规胰岛素治疗高钾血症的成年人。在胰岛素给药前或给药后一小时内给予帕替罗姆的患者被归类为干预组。以1:1的比例进行匹配。比较主要结局,即从基线到4 - 12小时间隔内钾的平均变化与最新值。次要结局包括净临床获益,定义为降钾干预次数的平均差异减去钾的变化。
最终分析纳入了133例接受帕替罗姆加胰岛素治疗的患者和133例仅接受胰岛素治疗的患者。参与者的平均年龄为71岁;43%为女性,31%自我认定为黑人,38%自我认定为拉丁裔。从基线(每组平均水平6.2 mEq/L)到4 - 12小时时间段,钾水平无显著变化(帕替罗姆组:-0.90 mEq/L,n = 78;仅胰岛素组:- 0.98 mEq/L,n = 81;p = 0.51)。计算得出的降钾净临床获益为-0.25,有利于帕替罗姆加胰岛素组;然而,这一差异未达到统计学意义。在估算肾小球滤过率(eGFR)>30 mL/min的亚组中,帕替罗姆组接受的降钾干预次数在数值上较少(0.63对1.12,p = 0.057)。
在这项针对ED环境中急性高钾血症患者的研究中,与单独使用胰岛素相比,在整个队列中同时给予帕替罗姆并未导致更持久的血钾降低。在肾功能正常的亚组中,支持辅助使用帕替罗姆的趋势值得进一步研究。